A decrease in pseudocholinesterase activity has been associated with the use of which medications?

A decrease in pseudocholinesterase activity has been associated with the use of which medications?

• A. Pancuronium, esmolol, meperidine
• B. Pancuronium, esmolol, metoclopramide
• C. Dantrolene, rocuronium, magnesium sulfate
• D. Metoclopramide, vecuronium, droperidol

Answer: (B)

The correct choice highlights that a decrease in pseudocholinesterase activity is particularly associated with the medications included in this group. Pseudocholinesterase is an enzyme that breaks down certain drugs, including some neuromuscular blockers and anesthetics. The medications mentioned—pancuronium, esmolol, and metoclopramide—are relevant as they have clinical implications in the context of pseudocholinesterase activity. Pancuronium is a neuromuscular blocker that can be influenced by factors affecting pseudocholinesterase, particularly in terms of duration of action when pseudocholinesterase levels are low. While esmolol is a beta-blocker and primarily does not interact with pseudocholinesterase, its mention could indicate a broader context of drug interactions—but the key focus remains on pancuronium in relation to pseudocholinesterase's role in neuromuscular transmission. In clinical practice, understanding which medications can be affected by pseudocholinesterase activity is crucial for safe and effective patient management, particularly in scenarios involving anesthesia, where neuromuscular agents are commonly used. Therefore, while esmolol may not be directly associated with pseudocholinesterase, its inclusion signifies the

The correct choice highlights that a decrease in pseudocholinesterase activity is particularly associated with the medications included in this group. Pseudocholinesterase is an enzyme that breaks down certain drugs, including some neuromuscular blockers and anesthetics.

The medications mentioned—pancuronium, esmolol, and metoclopramide—are relevant as they have clinical implications in the context of pseudocholinesterase activity. Pancuronium is a neuromuscular blocker that can be influenced by factors affecting pseudocholinesterase, particularly in terms of duration of action when pseudocholinesterase levels are low. While esmolol is a beta-blocker and primarily does not interact with pseudocholinesterase, its mention could indicate a broader context of drug interactions—but the key focus remains on pancuronium in relation to pseudocholinesterase's role in neuromuscular transmission.

In clinical practice, understanding which medications can be affected by pseudocholinesterase activity is crucial for safe and effective patient management, particularly in scenarios involving anesthesia, where neuromuscular agents are commonly used. Therefore, while esmolol may not be directly associated with pseudocholinesterase, its inclusion signifies the